In Reply

Oncologist. 2020 Aug;25(8):e1259. doi: 10.1634/theoncologist.2020-0336. Epub 2020 Jun 16.

Abstract

This letter to the editor responds to commentary on the recently reported PALBONET trial results, which focused on the role of Palbociclib in patients with low‐grade pancreatic neuroendocrine tumors.

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Pancreatic Neoplasms*
  • Piperazines*
  • Pyridines

Substances

  • Piperazines
  • Pyridines
  • palbociclib